{"id":394270,"date":"2020-12-07T08:33:10","date_gmt":"2020-12-07T13:33:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394270"},"modified":"2020-12-07T08:33:10","modified_gmt":"2020-12-07T13:33:10","slug":"sellas-life-sciences-and-3d-medicines-announce-exclusive-license-agreement-for-development-and-commercialization-of-galinpepimut-s-gps-and-gps-in-greater-china","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-and-3d-medicines-announce-exclusive-license-agreement-for-development-and-commercialization-of-galinpepimut-s-gps-and-gps-in-greater-china\/","title":{"rendered":"SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China"},"content":{"rendered":"
\n

\n – <\/em>
\n SELLAS to Potentially R<\/em>
\n eceive Up To $<\/em>
\n 202<\/em>
\n Million, Inclusive of $7.5 Million <\/em>
\n Upfront <\/em>
\n License Fee and <\/em>
\n $<\/em>
\n 8<\/em>
\n Million<\/em>
\n Near-term Milestone<\/em>
\n s, <\/em>
\n plus Tiered Royalties<\/em>
\n –<\/em>
\n \n <\/p>\n

\n –<\/em>
\n 3D Medicines to Lead Clinical Development and Commercialization of <\/em>
\n G<\/em>
\n P<\/em>
\n S<\/em>
\n and GPS+\u00a0<\/em>
\n in Greater China<\/em>
\n –<\/em>\n <\/p>\n

\n –\u00a0SELLAS <\/em>
\n Retain<\/em>
\n s<\/em>
\n Rights in the Rest of World, Including U<\/em>
\n nited <\/em>
\n S<\/em>
\n tates<\/em>
\n –<\/em>
\n \n <\/p>\n

NEW YORK and SHANGHAI, Dec. 07, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (\u201cSELLAS\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, and 3D Medicines Inc. (\u201c3DMed\u201d), a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced that they have entered into an Exclusive License Agreement granting rights to 3DMed to develop and commercialize SELLAS\u2019 lead late-stage clinical candidate, galinpepimut-S (GPS), as well as its next generation heptavalent immunotherapeuatic, GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory (mainland China, Hong Kong, Macau and Taiwan).\u00a0SELLAS retains sole rights to GPS and GPS+ outside of the Greater China area. Potential payments to SELLAS under the agreement could total $202 million in license fees and milestone payments, not including future royalties.<\/p>\n

GPS is an innovative potentially first-in-class WT1-targeting artificially engineered synthetic heteroclitic immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. In 2020, SELLAS commenced a Phase 3 clinical trial (the REGAL study) of GPS in patients with acute myeloid leukemia (AML) who have reached second complete remission.<\/p>\n

\u201cThis agreement represents an important achievement for SELLAS as we continue to progress our clinical development program for GPS. We are excited to collaborate with 3DMed on the development and commercialization of GPS in China. 3DMed, an ambitious biopharmaceutical company with development, registration and commercialization capabilities with a focus on developing next-generation immuno-oncology drugs and an experienced team, is a wonderfully complementary partner in bringing the potential of GPS to patients in Greater China. The collaboration begins to put in place essential elements designed to expand the reach of GPS outside the United States, following potential regulatory approvals,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.\u00a0\u00a0 \u201cThe completion of this agreement, amid the COVID-19 pandemic, shows the execution strength of our team. We are also pleased to have strengthened our balance sheet with the non-dilutive upfront license fee of $7.5 million with other potential milestones over the next several months.\u201d<\/p>\n

\u201cWe are very pleased to execute this exclusive license agreement of GPS and GPS+ in the Greater China area with SELLAS,\u201c said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3DMed. \u201cGPS and GPS+ are innovative therapeutics and, with growing need for new treatments, GPS\u2019 potential use as a monotherapy as well as in combination with our Envafolimab, an innovative subcutaneous PD-L1 antibody which we have just filed for marketing approval in China, could create significant value for both 3DMed and SELLAS. This partnership highly reflects the vision of 3DMed to help patients with cancer to live longer and better. We believe that the addition of the GPS and GPS+ assets to our clinical portfolio is an important synergistic and strategic step for 3DMed as this partnership will expand our company\u2019s therapeutic area expertise and improve our competitiveness.\u201d<\/p>\n

Under the financial terms of the agreement:<\/p>\n